Label Changes for:
Vidaza (azacitidine) for Injection
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2012
- tumor lysis syndrome, injection site necrosis,and Sweet’s syndrome (acute febrile neutrophilic dermatosis) ....added